Trial · NCT05701007
Outcomes28
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Body Mass Index (BMI) | 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Analysis excluded participants with missing data. | Kilogram per meter square | MEAN |
| PRIMARY | Prostate-Specific Antigen (PSA) | 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Analysis excluded participants with missing data. | Nanogram per milliliter | MEAN |
| PRIMARY | Alkaline Phosphatase (P-AFOS) | 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Analysis excluded participants with missing data. | Units per liter | MEAN |
| PRIMARY | Length of Follow-up | From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Years | MEAN |
| PRIMARY | Number of Participants With de Novo Metastasis | Within 2 months from index date; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Received Treatment for mCRPC and mCSPC | Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Diagnosed With mCSPC Who Progressed to mCRPC | Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Only reporting arm Participants Diagnosed With mCSPC is reported as this outcome measure was to be analyzed for participants who had mCSPC and they progressed to mCRPC. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Orchiectomy | Closest record any time from index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Undergone Palliative Radiology | Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Symptomatic Skeletal-Related Event (SSRE) | Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Osteoporosis | Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Were on Bone Medication | Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Who Were on Opioids | Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Classified Per Charlson Comorbidity Index (CCI) Scores | Up to 5 years before the index date (index date included); retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Classified Per Gleason Score | Closest record any time from index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approx.14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Based on Tumor Node Metastasis (TNM) Classification: T | Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Analysis excluded participants with missing data. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Based on Tumor Node Metastasis (TNM) Classification: N | Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Analysis excluded participants with missing data. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Based on Tumor Node Metastasis (TNM) Classification: M | Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Analysis excluded participants with missing data. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Based on Eastern Cooperative Oncology Group Performance Status (ECOG PS) | Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. Analysis excluded participants with missing data. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants According to Treatment Per Treatment Line for mPC: mCSPC Participants | Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months | Analysis population included all eligible participants whose data were included and observed for evaluation in the study. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for specified rows. Only reporting arm Participants Diagnosed With mCSPC is reported as this outcome measure was planned to be analyzed for this group. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05701007/outcomes